Biora Therapeutics is a biotechnology company. Co. supports patients and physicians during patients' life decisions with its suite of molecular tests, including: Innatal Prenatal Screen, which is a noninvasive prenatal test provided to women early in pregnancy to screen for risk of fetal chromosomal conditions, such as Down syndrome and sex chromosome disorders; and Resura Prenatal Test for Monogenic Disease, which is a test for monogenic diseases. Co.'s precision medicine development pipeline includes Recoverable Sampling System, which is an ingestible capsule platform designed to enable the collection, preservation, and analysis of samples. We show 8 historical shares outstanding datapoints in our PROG shares outstanding history coverage, used to compute PROG market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PROG market cap history over the course of time is important for investors
interested in comparing PROG's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PROG versus a peer is one thing; comparing
PROG market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PROG can fluctuate over the course of history.
With this page we aim to empower investors researching PROG by allowing them to research the PROG market cap history. |
Free PROG Email Alerts:
Video: The Importance of Market Cap
